Novo Nordisk’s once-a-week insulin injection, Awiqli, is set to hit the Indian market soon, offering a significant advance in diabetes management. The basal insulin will be distributed across the country through the company’s network of 4,500 distributors, according to a company statement on July 9, 2026.
Breakthrough in Diabetes Care
Awiqli is a novel basal insulin analog designed for once-weekly administration, reducing the injection frequency from daily to weekly. This innovation aims to improve adherence and quality of life for patients with type-1 and type-2 diabetes. Clinical trials have shown that Awiqli provides effective glycemic control with a lower risk of hypoglycemia compared to daily insulin regimens.
“This is a game-changer for diabetes patients who often struggle with daily injections,” said Dr. Anoop Misra, Chairman of Fortis C-DOC Center for Diabetes. “The convenience of a once-weekly injection can significantly improve compliance and outcomes.”
Availability and Distribution
Novo Nordisk plans to make Awiqli available through its extensive distribution network, covering both urban and rural areas. The company expects the product to be accessible in major pharmacy chains and hospitals across India. Pricing details have not been disclosed, but the company aims to ensure affordability.
India has an estimated 101 million people living with diabetes, according to the International Diabetes Federation. The launch of Awiqli could address a critical need for more convenient insulin therapies.
Impact on Patients
Patients currently using daily basal insulin may transition to weekly injections under medical supervision. The reduced injection burden is expected to benefit those with needle phobia, busy schedules, or difficulty managing multiple daily doses. “I’m hopeful this will make my life easier,” said Ramesh K., a type-2 diabetes patient from Mumbai. “Daily injections are a constant reminder of my condition.”
Novo Nordisk has invested heavily in research to develop long-acting insulins. Awiqli received approval from the Drug Controller General of India (DCGI) in early 2026 after successful clinical trials involving over 3,000 participants.
Expert Opinions
Endocrinologists have welcomed the development but caution that not all patients may be suitable candidates. “While once-weekly insulin is a major step, individualization of therapy remains key,” said Dr. Shashank Joshi, President of the Indian Academy of Diabetes. “Patients should consult their doctors before switching.”
The launch positions Novo Nordisk ahead of competitors in the race for ultra-long-acting insulins. Other pharmaceutical companies are also developing similar products, but Awiqli is among the first to reach the Indian market.
